Send to

Choose Destination
Bioanalysis. 2016 Aug;8(15):1623-1633. Epub 2016 Jul 11.

Mass spectrometric immunoassays for discovery, screening and quantification of clinically relevant proteoforms.

Author information

The Biodesign Institute at Arizona State University, Tempe, AZ, USA.


Human proteins can exist as multiple proteoforms with potential diagnostic or prognostic significance. MS top-down approaches are ideally suited for proteoforms identification because there is no prerequisite for a priori knowledge of the specific proteoform. One such top-down approach, termed mass spectrometric immunoassay utilizes antibody-derivatized microcolumns for rapid and contained proteoforms isolation and detection via MALDI-TOF MS. The mass spectrometric immunoassay can also provide quantitative measurement of the proteoforms through inclusion of an internal reference standard into the analytical sample, serving as normalizer for all sample processing and data acquisition steps. Reviewed here are recent developments and results from the application of mass spectrometric immunoassays for discovery of clinical correlations of specific proteoforms for the protein biomarkers RANTES, retinol binding protein, serum amyloid A and apolipoprotein C-III.


MALDI; MS; immunoaffinity; plasma; proteoform

[Indexed for MEDLINE]
Free PMC Article

Conflict of interest statement

Financial & competing interests disclosure This work was supported in part by Grants R01DK082542 and R24DK090958 from the National Institute of Diabetes and Digestive and Kidney Diseases. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center